Cantourage Group SE Boosts Profitability in Q1 2026

Cantourage Group SE reported a notable increase in profitability for the first quarter of 2026, largely driven by a strategic focus on premium products and international expansion. The company's revenue grew by 11.0% from the previous quarter, reaching EUR 20.6 million. The EBITDA margin improved significantly to 10.6%, while the company maintains a strong financial stance with a net cash position of EUR 8.8 million.

The UK market has shown strong performance, contributing 41.3% to consolidated revenue, second only to Germany, which accounts for 51.5%. Cantourage’s position in the European medical cannabis market is bolstered by this geographic diversification and robust market presence across various countries.

Looking forward, Cantourage aims to leverage regulatory changes in Germany as an opportunity to solidify its market presence. Investments in telemedicine and digitalization are pivotal to Cantourage’s strategy, as they continue to innovate within the medical cannabis sector.